

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 55921

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Efficacy and Safety of S-1 Maintenance Therapy in Advanced NSCLC Patients

Chun-Ling Mu *et al.* **therapy in advanced NSCLC patients**

Abstract

BACKGROUND

Previous reports demonstrated that S-1 has remarkable effects in the maintenance treatment of advanced non-small-cell lung cancer and less toxic and side effects than conventional drugs

AIM

To investigate the efficacy and safety of S-1 maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC).

METHODS

Ninety-four patients with non-small cell lung cancer admitted in our hospital from September 2015 to April 2018 were included in the study and divided into the S-1 group (47 cases) and the gemcitabine group (47 cases) by random digital table method. The S-1

Match Overview

1	Internet 50 words crawled on 01-May-2020 wclc2018.iaslc.org	2%
2	Internet 40 words crawled on 13-May-2020 worldwidescience.org	2%
3	Internet 39 words crawled on 25-Jul-2020 pesquisa.bvsalud.org	1%
4	Internet 31 words crawled on 04-Aug-2020 mafiadoc.com	1%
5	Crossref 29 words Tetsuro Yamashita , Yuji Ueda , Nobuaki Fuji , Tsuyoshi Itoh , Hideaki Kurioka , Tetsuhiko Shirasaka , Hisakazu Yamagish	1%
6	Internet 27 words crawled on 26-Jul-2020 www.semanticscholar.org	1%
7	Crossref 24 words "Abstracts", <i>Journal of Thoracic Oncology</i> , 2009	1%
8	Crossref 19 words Hideki Ueno , Tatsuya Ioka , Masafumi Ikeda , Shinichi Ohka wa et al. "Randomized Phase III Study of Gemcitabine Plu	1%

Any time ▾

<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32987>

Author: Kaoru Tanaka, Satoshi Morita, Masahi... Publish Year: 2020

<https://www.ncbi.nlm.nih.gov/pubmed/28625650>

Cited by: 6 Author: Seiji Niho, Yuichiro Ohe, Hironobu Ohmat...

Publish Year: 2017

bing.com/images



Authors	Substrate	Site	Regulators	GHG	GHG	GHG	GHG
Year	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
1998	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2000	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2002	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2004	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2006	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2008	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2010	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2012	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2014	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2016	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2018	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2020	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG
2022	Regulator	in μM	Concentration	GHG	GHG	GHG	GHG

[See all images >](#)

<https://pubmed.ncbi.nlm.nih.gov/28625650>



国内版

国际版

Efficacy and Safety of S-1 Maintenance Therapy in Advanced NSCLC



ALL

IMAGES

VIDEOS

903,000 Results

Any time ▼

A randomized phase 3 study of maintenance therapy with S-1 ...

<https://pubmed.ncbi.nlm.nih.gov/32484914>

A randomized phase 3 study was performed to investigate the **efficacy and safety of maintenance therapy** with **S-1** after **induction therapy** with carboplatin plus **S-1** in patients with **advanced squamous non-small cell lung cancer (NSCLC)**.

Author: Kaoru Tanaka, Satoshi Morita, Masahik... **Publish Year:** 2020

Switch Maintenance Chemotherapy Using S-1 With or Without ...

<https://pubmed.ncbi.nlm.nih.gov/28625650>

Switch maintenance chemotherapy with **S-1** in combination with continuation **maintenance chemotherapy** with bevacizumab yielded modest **efficacy** with mild and acceptable toxicities. **Switch Maintenance Chemotherapy Using S-1 With or Without Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer: A Phase II Study**

Cited by: 6 **Author:** Seiji Niho, Yuichiro Ohe, Hironobu Ohmatsu...

Publish Year: 2017

A randomized phase 3 study of maintenance therapy with S-1 ...

<https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32987>

The most common toxicities during **maintenance therapy** with **S-1** included anorexia, anemia, and fatigue, but most cases were not severe. Conclusions Continued **maintenance** with **S-1** plus BSC is an **effective** and well-tolerated **treatment** option for patients with **advanced squamous NSCLC** previously treated with carboplatin plus **S-1**.

Author: Kaoru Tanaka, Satoshi Morita, Masahik... **Publish Year:** 2020



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

4,490,000 Results

Any time ▾

[Switch Maintenance Chemotherapy Using S-1 With or Without ...](#)

<https://pubmed.ncbi.nlm.nih.gov/28625650>

Switch Maintenance Chemotherapy Using **S-1** With or Without Bevacizumab in Patients With **Advanced Non-Small Cell Lung Cancer**: A Phase II Study. **Switch maintenance chemotherapy** with **S-1** in combination with continuation **maintenance chemotherapy** with bevacizumab yielded modest **efficacy** with mild and acceptable toxicities.

Cited by: 6

Author: Seiji Niho, Yuichiro Ohe, Hironobu Ohmat...

Publish Year: 2017

[A randomized phase 3 study of maintenance therapy with S-1 ...](#)

<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32987>

The most common toxicities during **maintenance therapy** with **S-1** included anorexia, anemia, and fatigue, but most cases were not **severe**. Conclusions. Continued **maintenance** with **S-1** plus BSC is an **effective** and well-tolerated **treatment** option for patients with **advanced squamous NSCLC** previously treated with carboplatin plus **S-1**.

Author: Kaoru Tanaka, Satoshi Morita, Masahi...

Publish Year: 2020

[\[Efficacy and safety of gefitinib in maintenance therapy ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/18756941>

1. Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):221-4. [**Efficacy and safety** of gefitinib in **maintenance therapy** for **patients** with **advanced non-small cell lung cancer**].

Cited by: 4

Author: Wang Mz, Zhong W, Zhang L, Li Ly, Wan...

Publish Year: 2008

[Efficacy and safety of rh-endostatin \(Endostar\) combined ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/30152052>

Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed **maintenance** in **non-small cell lung cancer**: A retrospective comparison with standard chemotherapy. Zhou **S**(1), Zuo L(2), He X(1), Pi J(2), Jin J(2), Shi Y(1).

Author: Shengyu Zhou, Lijie Zuo, Xiaohui He, ...

Publish Year: 2018